FOSTER CITY, Calif. (AP) ? Gilead Sciences says it will spend $11 billion to buy drug developer Pharmasset at a price more than 88 percent over the stock's latest closing price in a bet on its experimental hepatitis C treatments.
Gilead says it will pay $137 per share in cash for each Pharmasset share. That stock closed at $72.67 on Friday.
Pharmasset said earlier this month it had started late-stage clinical trials of an experimental hepatitis C drug. It also plans two other late-stage trials in 2012.
Hepatitis C is a viral infection that often has no symptoms but which can lead to life-threatening liver damage.
Gilead will pay for the deal with cash on hand, bank debt and senior unsecured notes. It expects the acquisition to close in next year's first quarter.
Associated Pressios 5 features ellen degeneres show ellen degeneres show david guetta david guetta work of art iphone update
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন